USA — Elevance Health, Inc., formerly known as Anthem, Inc., has completed the purchase of Paragon Healthcare, a Texas-based provider of infusion services, strengthening Elevance Health’s commitment to providing access to specialty pharmaceuticals for those with chronic and severe diseases.

This acquisition is part of Elevance Health’s larger aim to deliver integrated healthcare services, and it is consistent with a trend of consolidation in the healthcare business as corporations strive to provide more complete care.

Elevance Health intends to broaden Paragon Healthcare’s geographic reach and increase its therapeutic solutions to ensure that its members have prompt and accessible access to drugs.

The goal is to improve the health of humanity by assisting consumers, families, and communities throughout their care journeys.

Elevance Health serves about 117 million people through its medical, digital, pharmaceutical, behavioral, clinical, and complex care solutions portfolio.

Pete Haytaian, Elevance Health’s executive vice president and president of Carelon, expressed his delight at welcoming Paragon Healthcare to the Elevance Health family.

He went on to say that this will give members more options for where they get their injected medications, which will eventually reduce barriers to care, boost medication adherence, minimize healthcare costs, and better support members’ overall health.

Paragon Healthcare specializes in the delivery of infusible and injectable medicines, servicing over 35,000 patients in eight states through over 40 ambulatory infusion centres and home infusion pharmacy locations.

Elevance purchased specialist pharmacy BioPlus in February of last year, which similarly specializes on providing specialized drugs to people with chronic illnesses such as cancer and multiple sclerosis. BioPlus is also a Carelon subsidiary.

Elevance Health reported a US$6 billion profit for 2023 on revenue of more than $171 billion in January.

For all the latest healthcare industry news from Africa and the World, subscribe to our NEWSLETTER, and YouTube Channel, follow us on Twitter and LinkedIn, and like us on Facebook.